Cancer Immunology and Immunotherapy
Cancer Immunology represents a strong and developing theme within the Institute of Immunology and Immunotherapy. Building on exceptional international interest within this area, investigators within the Institute work within a broad range of interests and are characterised by a strong translational focus.
Basic Science Lead
Professor Benjamin Willcox
Professor of Molecular Immunology
Professor Gary Middleton
Professor of Medical Oncology
Our aim is to make significant contributions to understanding the fundamental processes that underlie the immune response to cancer and to translate this into therapeutic opportunities with our NHS partners. Our plans will see us strengthen national and international collaborations, deepen our interactions with industry and contribute to training within this exciting area of biology.
Cancer Immunology and Immunotherapy Principal Investigators
|Principal Investigator||Research Interest|
|Professor Benjamin Willcox
||Novel tumour antigens and unconventional T cell function, particularly in immunosurveillance of cellular stress.
|Professor Gary Middleton
||Tumour immunobiology and the tumour microenviroment with a particular focus on MDSCs.
|Professor Paul Moss
||Application of translational immunological research in the study of human disease.
|Dr Francis Mussai
||Interactions between paediatric and adult cancers and the immune system.
|Dr Yuk Ting Ma
||Understanding how epigenetic therapies may be used to reverse resistance to chemotherapy.
|Dr Graham Taylor
||Immune system in health and disease and how best to harness the immune system to treat cancer.
|Dr Claire Shannon-Lowe
||Epstein-Barr virus (EBV) entry into epithelial cells, T cells and Natural Killer cells.
|Dr Heather Long
||Developing immune-based therapies for the treatment of EBV-associated and non virus-associated lymphomas.
|Dr Fiyaz Mohammed
||Immune cell surface receptor/ligand interactions relevant to cancer using X-ray crystallography.
|Dr Jianmin Zuo
||Natural Killer (NK) cells in leukaemia.
|Dr Carmela De Santo
||Tumour immunosuppression and myeloid derived suppressor cells.